Diadexus, Inc. is a molecular diagnostics company focused on the development and commercialization of immunoassay tests that help clinicians assess risk and monitor progression of cardiovascular, inflammatory and infectious diseases. Its core business centers on proprietary biomarker assays that measure levels of enzymes and proteins implicated in disease processes, enabling more informed patient management and treatment strategies.
The company’s flagship offering is the PLAC® Test, an FDA-cleared immunoassay for measuring lipoprotein-associated phospholipase A2 (Lp-PLA2), a marker linked to vascular inflammation and cardiovascular risk. In addition to cardiovascular biomarkers, Diadexus has expanded its product portfolio to include assays for early detection of sepsis and immunodiagnostic tests for antibiotic-resistant bacteria, supporting hospital laboratories and physician practices in critical care and infectious disease settings.
Diadexus markets its products in the United States and through a network of international distribution partners, serving clinical laboratories, hospitals and medical research institutions. Its assays are performed on widely adopted clinical platforms, facilitating integration into existing laboratory workflows and broadening access to advanced diagnostic information worldwide.
Headquartered in South San Francisco, California, Diadexus was founded in 1988 and has maintained a focus on innovation in molecular diagnostics. The company’s management team combines scientific expertise and industry experience aimed at advancing precision medicine through commercially available biomarker tests.
AI Generated. May Contain Errors.
Free DDXS Stock Alerts